AstraZeneca nabs breakthrough status, as $7B ADC races to blockbuster status
A rapid breast cancer approval came just before New Year’s for AstraZeneca and Daiichi Sankyo’s billion-dollar antibody drug conjugate Enhertu, but the plan was never to stop there.
Today, AstraZeneca said they received breakthrough status for Enhertu in HER2-positive non-small cell lung cancer. It’s the second such designation they’ve received in a week, after the FDA granted the same recognition to Enhertu in gastric cancer. The twin designations set the British drugmaker up to market the drug in three different indications, a key validation for the massive deal CEO Pascal Soriot signed in 2019.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 83,100+ biopharma pros reading Endpoints daily — and it's free.